OBJECTIVE: To review the evaluation and management of skeletal health in patients with celiac disease (CD), and to make recommendations on screening, diagnosis, treatment and follow-up of low bone mineral density (BMD) in CD patients. METHODS: A multidisciplinary team developed clinically relevant questions for review. An electronic search of the literature was conducted using the MEDLINE and EMBASE databases from 1996 to 2010. All original studies, reviews and guidelines, both pediatric and adult, were included. A document summarizing the results of the review and proposed recommendations was prepared and underwent multiple revisions until consensus was reached. RESULTS: At diagnosis, approximately one-third of adult CD patients have osteoporosis, one-third have osteopenia and one-third have normal BMD. Children with CD have low bone mass at diagnosis. Adult and pediatric CD patients are at increased risk of fractures. DISCUSSION: For adults, serum calcium, albumin, 25(OH) vitamin D3, parathyroid hormone and 24 h urine calcium testing should be performed at diagnosis; patients with 'classic' CD and those at risk for osteoporosis should undergo a dual x-ray absorptiometry scan. An abnormal baseline dual x-ray absorptiometry scan should be repeated one to two years after initiation of a gluten-free diet (GFD). For children, BMD should be assessed one year after diagnosis if GFD adherence is not strict. A GFD is the most important treatment for bone loss. Supplemental antiresorptives may be justified in those who remain at high fracture risk (eg, postmenopausal women, older men) after implementation of a GFD. CONCLUSION: Current evidence does not support the screening of all CD patients for low BMD at diagnosis. Follow-up BMD assessment should be performed one to two years after initiation of a GFD.
OBJECTIVE: To review the evaluation and management of skeletal health in patients with celiac disease (CD), and to make recommendations on screening, diagnosis, treatment and follow-up of low bone mineral density (BMD) in CDpatients. METHODS: A multidisciplinary team developed clinically relevant questions for review. An electronic search of the literature was conducted using the MEDLINE and EMBASE databases from 1996 to 2010. All original studies, reviews and guidelines, both pediatric and adult, were included. A document summarizing the results of the review and proposed recommendations was prepared and underwent multiple revisions until consensus was reached. RESULTS: At diagnosis, approximately one-third of adult CDpatients have osteoporosis, one-third have osteopenia and one-third have normal BMD. Children with CD have low bone mass at diagnosis. Adult and pediatric CDpatients are at increased risk of fractures. DISCUSSION: For adults, serum calcium, albumin, 25(OH) vitamin D3, parathyroid hormone and 24 h urine calcium testing should be performed at diagnosis; patients with 'classic' CD and those at risk for osteoporosis should undergo a dual x-ray absorptiometry scan. An abnormal baseline dual x-ray absorptiometry scan should be repeated one to two years after initiation of a gluten-free diet (GFD). For children, BMD should be assessed one year after diagnosis if GFD adherence is not strict. A GFD is the most important treatment for bone loss. Supplemental antiresorptives may be justified in those who remain at high fracture risk (eg, postmenopausal women, older men) after implementation of a GFD. CONCLUSION: Current evidence does not support the screening of all CDpatients for low BMD at diagnosis. Follow-up BMD assessment should be performed one to two years after initiation of a GFD.
Authors: Annie W C Kung; Chih-Hsing Wu; Akira Itabashi; Joon Kiong Lee; Hyoung Moo Park; Yanling Zhao; Wing P Chan; David L Kendler; Edward S Leib; E Michael Lewiecki; John P Bilezikian; Sanford Baim Journal: J Clin Densitom Date: 2010-07-21 Impact factor: 2.617
Authors: M S Scotta; S Salvatore; A Salvatoni; M De Amici; D Ghiringhelli; M Broggini; L Nespoli Journal: Am J Gastroenterol Date: 1997-08 Impact factor: 10.864
Authors: M Pazianas; G P Butcher; J M Subhani; P J Finch; L Ang; C Collins; R P Heaney; M Zaidi; J D Maxwell Journal: Osteoporos Int Date: 2004-06-17 Impact factor: 4.507
Authors: Markku Mäki; Kirsi Mustalahti; Jorma Kokkonen; Petri Kulmala; Mila Haapalahti; Tuomo Karttunen; Jorma Ilonen; Kaija Laurila; Ingrid Dahlbom; Tony Hansson; Peter Höpfl; Mikael Knip Journal: N Engl J Med Date: 2003-06-19 Impact factor: 91.245
Authors: A Tommasini; T Not; V Kiren; V Baldas; D Santon; C Trevisiol; I Berti; E Neri; T Gerarduzzi; I Bruno; A Lenhardt; E Zamuner; A Spanò; S Crovella; S Martellossi; G Torre; D Sblattero; R Marzari; A Bradbury; G Tamburlini; A Ventura Journal: Arch Dis Child Date: 2004-06 Impact factor: 3.791
Authors: Jacalyn A See; Katri Kaukinen; Govind K Makharia; Peter R Gibson; Joseph A Murray Journal: Nat Rev Gastroenterol Hepatol Date: 2015-09-22 Impact factor: 46.802
Authors: Carolina Ciacci; Paul Ciclitira; Marios Hadjivassiliou; Katri Kaukinen; Jonas F Ludvigsson; Norma McGough; David S Sanders; Jeremy Woodward; Jonathan N Leonard; Gillian L Swift Journal: United European Gastroenterol J Date: 2015-04 Impact factor: 4.623
Authors: John A Kanis; Nicholas C Harvey; Cyrus Cooper; Helena Johansson; Anders Odén; Eugene V McCloskey Journal: Arch Osteoporos Date: 2016-07-27 Impact factor: 2.617
Authors: Gloria Galli; Edith Lahner; Laura Conti; Gianluca Esposito; Maria Carlotta Sacchi; Bruno Annibale Journal: United European Gastroenterol J Date: 2018-06-12 Impact factor: 4.623